Managing RCC after progression: translating evidence into clinical practice

1. Approximately what proportion of malignant renal tumours in adults are clear-cell RCC?

2. Which non-clear-cell RCC subtype is the most common?

3. South Africa has a higher prevalence of pRCC than Western populations 23- 36%.

4. Current management of advanced clear-cell RCC per guidelines includes:

5. Which biomarker was highlighted as being unreliable for treatment selection in RCC?

6. Cabozantinib-containing regimens are preferred because they simultaneously target:

7. Primary resistance to IO + TKI therapy may be observed as early as_____ with a non- inflamed tumour, high M2 macrophages/ Tregs no initial shrinkage:

8. Which mechanism is associated with angiogenic bypass resistance under VEGFR inhibition?

9. In the CABOSUN trial at the data cut-off of September 15, 2016, cabozantinib demonstrated an investigator-assessed median progression-free survival (PFS) of 8.2 months and an overall survival of_____:

10. In the METEOR study, cabozantinib was compared with everolimus and showed an overall survival benefit of 21.4 months vs____months with everolimus: